Reply to: “Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything” and “More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations”

Journal of Hepatology

Volumn 68, Issue 1, 2018, Pages 219-220

  Beste, Lauren A ^a,b   Green, Pamela K ^a   Berry, Kristin ^a   Kogut, Matthew J ^a,b   Allison, Stephen K ^a,b   Ioannou, George N ^a,b  

^a Veterans Affairs Puget Sound Health Care System   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER PATIENT; DECOMPENSATED LIVER CIRRHOSIS; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85031688754     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.09.011     Document Type: Letter

References (1)

1. Ioannou, G.N., Beste, L.A., Chang, M.F., Green, P.K., Lowy, E., Tsui, J.I., et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans affairs national health care system. Gastroenterology 151 (2016), 457–471 e5.